Latest Information Update: 08 Dec 2014
At a glance
- Originator Edgemont Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes - Generalised anxiety disorder
Highest Development Phases
- Phase Unknown Generalised anxiety disorder
Most Recent Events
- 08 Dec 2014 Investigation in Generalised anxiety disorder in USA (unspecified route)
- 08 Dec 2014 EDG 008 is available for licensing in World as of 08 Dec 2014. http://edgemontpharma.com/